# Celularity (stock symbol: CELU) Logo in transparent PNG and SVG formats

## Celularity Logo large

### Celularity Logo large Download PNG (22.5 KB)

![Celularity Logo large Download PNG (22.5 KB)](/img/orig/CELU_BIG-d1e6bc39.png)

### Celularity Logo large Download SVG (4.55 KB)

![Celularity Logo large Download SVG (4.55 KB)](/img/orig/CELU_BIG-eb6eff02.svg)

## Celularity Logo icon format

### Celularity Logo icon format Download PNG (38.55 KB)

![Celularity Logo icon format Download PNG (38.55 KB)](/img/orig/CELU-43abc6a1.png)

### Celularity Logo icon format Download SVG (1.41 KB)

![Celularity Logo icon format Download SVG (1.41 KB)](/img/orig/CELU-a361caaf.svg)

## Celularity Logo large for dark backgrounds

### Celularity Logo large for dark backgrounds Download PNG (14.13 KB)

![Celularity Logo large for dark backgrounds Download PNG (14.13 KB)](/img/orig/CELU_BIG.D-5e4590bb.png)

### Celularity Logo large for dark backgrounds Download SVG (4.01 KB)

![Celularity Logo large for dark backgrounds Download SVG (4.01 KB)](/img/orig/CELU_BIG.D-a4c9a83c.svg)

## Celularity Logo icon format for dark backgrounds

### Celularity Logo icon format for dark backgrounds Download PNG (23 KB)

![Celularity Logo icon format for dark backgrounds Download PNG (23 KB)](/img/orig/CELU.D-9facbe60.png)

### Celularity Logo icon format for dark backgrounds Download SVG (1.38 KB)

![Celularity Logo icon format for dark backgrounds Download SVG (1.38 KB)](/img/orig/CELU.D-bbe44713.svg)

## About Celularity

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

1. Website domain: celularity.com
2. Employees: 225
3. Marketcap: $97.44 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
